Brenning G, Wibell L, Bergström R
Eur J Clin Invest. 1985 Oct;15(5):242-7. doi: 10.1111/j.1365-2362.1985.tb00177.x.
Serum beta 2-microglobulin (S-beta 2m) was determined before treatment in fifty patients with multiple myeloma (MM), twenty-two of which had pure Bence Jones (BJ) myeloma. S-beta 2m was related to clinical stage before, but not after, a correction of S-beta 2m values for co-existent raised S-creatinine values (greater than 106 mumol 1-1). However, S-beta 2m as well as corrected beta 2m was a parameter of prognostic value. The median expected survival time was 14 months at S-beta 2m values greater than 8.0 mg 1(-1) and 56 months at values less than 3.5 mg 1(-1). A response to treatment was associated with a decrease of S-beta 2m and a stationary course with unchanged values, whereas a relapse or progressive disease was connected with an increase. In 'beta 2m producers', i.e. patients with a clear initial high S-beta 2m, serial determinations are of value for monitoring patients with MM. In particular, this is the case in BJ myelomas, as they lack a quantifiable serum M-component. With respect to beta 2m no difference was found between BJ and other patients with MM.
在50例多发性骨髓瘤（MM）患者治疗前测定了血清β2-微球蛋白（S-β2m），其中22例为单纯本-周蛋白（BJ）骨髓瘤。在对S-β2m值进行校正以排除同时存在的血清肌酐值升高（大于106μmol/L）之前，S-β2m与临床分期相关，校正后则无相关性。然而，S-β2m以及校正后的β2m都是具有预后价值的参数。当S-β2m值大于8.0mg/L时，预期生存时间中位数为14个月；当值小于3.5mg/L时，预期生存时间中位数为56个月。治疗反应与S-β2m降低相关，病情稳定时S-β2m值不变，而复发或疾病进展则与S-β2m升高有关。在“S-β2m产生者”，即初始S-β2m明显升高的患者中，连续测定对于监测MM患者具有价值。特别是在BJ骨髓瘤中，由于它们缺乏可定量的血清M成分，情况更是如此。就β2m而言，如果BJ骨髓瘤患者和其他MM患者之间没有差异。
